20/20 Biolabs Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2M+16.4% YoYTTM through 30 Jun 2026
Net Income -$5.8MTTM through 30 Jun 2026
Free Cash Flow -$2.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 31.5% |
| EBITDA Margin | -213.0% |
| Operating Margin | -215.7% |
| Net Margin | -285.0% |
Returns
-358.8%ROE
-95.0%ROA
Balance Sheet Health
Current Ratio1.99x
Cash & Equivalents$4.5M
Quality Metrics
Altman Z-Score-8.77
Piotroski F-Score5 / 9
FCF Margin-136.8%
Rule of 40-92.3
Multi-Year Trend
RevenueFY2025: $2M
Diluted EPS-$0.97TTMFY2025: $-0.76
Dividend
No dividend
Capital Allocation
R&D Spend$672.7K
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| OneTest for Cancer | $1.8M | ||
| BioCheck | $163.6K | ||
| Clinical Laboratory Innovation Accelerator (CLIAx) | $81.8K |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.